Trial: NCT02760498

Disease Type: Sarcoma
Status: Open

Trial Information

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death (PD-1) in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Click here for more information

This trial is available at:

Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127

For more information, please contact: